Translational Development Acquisition (TDACW) Equity Average (2024 - 2026)

Translational Development Acquisition has reported Equity Average for 3 years, with the latest figure at -$6.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 15.79% year-over-year to -$6.7 million; the trailing twelve-month figure through Mar 2026 stood at -$6.7 million (down 15.79% YoY), and the FY2025 full-year result was -$6.1 million, down 98.84% from the prior year.
• Equity Average for Q1 2026 stood at -$6.7 million, down from -$6.5 million in the prior quarter.
• The five-year high for Equity Average was -$508500.5 in Q2 2024, with the low at -$6.7 million in Q1 2026.
• Historically, Equity Average has averaged -$4.4 million across 3 years, with a median of -$5.9 million in 2025.
• Annual changes were most pronounced in 2025 — Equity Average tumbled 1090.86% — and 2026, when it declined 15.79%.
• Translational Development Acquisition's Equity Average stood at -$3.1 million in 2024, then slumped by 109.49% to -$6.5 million in 2025, then declined by 3.43% to -$6.7 million in 2026.
• The last three Equity Average figures came in at -$6.7 million (Q1 2026), -$6.5 million (Q4 2025), and -$6.3 million (Q3 2025), per Business Quant data.